Q-omics provides the consensus-scored GRM4 profile across patient tissues and cancer cell-line models. GRM4 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, GRM4 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, GRM4 RNA expression shows 14,184 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, THCA, and THYM as cancer lineages where GRM4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GRM4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GRM4 survival associations across molecular data types. GRM4 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GRM4 RNA expression–survival associations across cancer types. High GRM4 expression shows unfavorable associations in KIRC, UVM, LIHC, LUSC and THCA, but favorable associations in LGG. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for GRM4 RNA expression.
This table summarizes GRM4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for GRM4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GRM4 shows higher tumor expression in THCA, HNSC, BRCA, LUSC, BLCA and COAD. The THCA box plot shows higher GRM4 RNA expression in tumor versus normal tissue (log2 FC = +1.486, t-test p < 0.001).
This table shows molecular features associated with GRM4 in patient tissues and cancer cell lines. In patient samples, GRM4 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, GRM4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and LARGE_INTESTINE.
